share_log

信邦制药(002390.SZ)：2023年上半年销售费用占收入比例约5%、管理费用占收入比例约6%

Xinbang Pharmaceutical (002390.SZ): In the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue

Gelonghui Finance ·  Mar 15 05:02

Gelonghui, March 15 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue. The company effectively controlled various expenses through budget management. The sales expenses incurred in the first half of 2023 were 173.6613 million yuan, a decrease of about 10% over the same period of the previous year; management expenses were 206.643 million yuan, a decrease of about 8% over the same period last year. Currently, the company's various operations are smooth and orderly. The company's business involves the three major sectors of medical services, pharmaceutical distribution and pharmaceutical manufacturing. In the first half of 2023, the company's pharmaceutical manufacturing sector achieved revenue of 386.1834 million yuan, accounting for 9.62% of the company's revenue.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment